论文部分内容阅读
目的 探讨经直肠超声引导前列腺 13点系统穿刺活检术诊断前列腺癌的临床价值。方法 共16 0例直肠指诊阳性和 (或 )前列腺特异抗原 (PSA)值 >4ng/ml的患者接受了经直肠超声引导前列腺 13点系统穿刺活检术 ,即按照Eskew描述的方法 ,在标准的经直肠超声引导前列腺 6点系统穿刺活检术的同时 ,增加在前列腺的中间部位及前列腺两侧旁正中线远侧的穿刺点数 ,共穿刺活检 13点。将增加的 7点活检部位的病理结果与标准的 6点穿刺活检术进行比较。结果 16 0例患者中有 5 6例确诊为前列腺癌 ( 5 6 / 16 0 ) ,占 35 %。 5 6例前列腺癌患者若仅采用标准的经直肠超声引导 6点前列腺穿刺活检术 ,将有 12例患者漏诊 ,占 2 1%。所有接受经直肠超声引导前列腺 13点系统穿刺活检术的患者无一例出现严重的并发症。结论 经直肠超声引导前列腺13点系统穿刺活检术可明显提高前列腺癌的临床检出率 ,是一种安全、有效的前列腺系统穿刺活检术式 ,值得在临床推广应用。
Objective To investigate the clinical value of transrectal ultrasound guided prostatic 13-point system biopsy in the diagnosis of prostate cancer. Methods A total of 160 patients undergoing transrectal digital and / or prostate specific antigen (PSA)> 4 ng / ml underwent transrectal ultrasound-guided prostate 13-point system biopsy in accordance with the method described by Eskew in a standard Transrectal ultrasound guided prostatic 6-point system biopsy at the same time, increase in the middle of the prostate and prostate on both sides of the median line next to the puncture point, a total of biopsy 13 points. The pathological results of the additional 7-point biopsy site were compared with a standard 6-point biopsy. Results 56 out of 160 patients were diagnosed as prostate cancer (56/160), accounting for 35%. Of the 6 patients with prostate cancer who underwent only 6-point prostate biopsy using standard transrectal ultrasound alone, 12 patients missed 21%. None of the patients who underwent transrectal ultrasound-guided prostatic 13-point biopsy had any serious complication. Conclusion Transrectal ultrasound-guided prostatic 13-point system biopsy can significantly improve the clinical detection rate of prostate cancer. It is a safe and effective method for prostatic biopsy, which is worthy of clinical application.